{"status": "ok", "totalResults": 4, "articles": [{"source": {"id": null, "name": "Vancouver Sun"}, "author": "Cheryl Chan", "title": "With a whiff of the European fire ant, spiders get antsy: SFU study - Vancouver Sun", "description": "Despite the findings, people should not use aggressive and invasive European fire ants to get rid of spiders, said researchers.", "url": "https://vancouversun.com/news/with-a-whiff-of-the-european-fire-ant-spiders-get-antsy-sfu-study", "urlToImage": "https://smartcdn.prod.postmedia.digital/vancouversun/wp-content/uploads/2021/06/261668451-spidey2-w.jpg", "publishedAt": "2021-06-02T20:39:16Z", "content": "Article content\r\nScared of spiders? Ants could help.\r\nA new study by Simon Fraser University researchers has found that chemicals given off by ants, their natural predator, are a deterrent for spider\u2026 [+2291 chars]"}, {"source": {"id": null, "name": "City A.M."}, "author": "Andrew Muir", "title": "Expansion of Pfizer manufacturing capacity in Belgium approved by EMA body - City A.M.", "description": "The Committee for Human Medicines, part of the European Medicines Agency (EMA), has recommended the approval of additional manufacturing and filling lines at Pfizer's manufacturing site in Puurs, Belgium.", "url": "https://www.cityam.com/expansion-of-pfizer-manufacturing-capacity-in-belgium-approved-by-ema-body/", "urlToImage": "https://www.cityam.com/wp-content/uploads/Reuters_Direct_Media/UKOnlineReportDomesticNews/tagreuters.com2021binary_LYNXMPEH4B1M4-VIEWIMAGE.jpg", "publishedAt": "2021-06-02T16:29:00Z", "content": "The Committee for Human Medicines, part of the European Medicines Agency (EMA), has recommended the approval of additional manufacturing and filling lines at Pfizer\u2019s manufacturing site in Puurs, Bel\u2026 [+340 chars]"}, {"source": {"id": null, "name": "Acrofan.com"}, "author": null, "title": "Moderna Announces New Drug Substance Production Agreement with Lonza in the Netherlands - ACROFAN USA", "description": "New agreement with Lonza will increase drug substance production in Europe by the fourth quarter 2021Lonza Geleen will support the production of an additional 300 million doses per yearCAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna, Inc. (Nasdaq: MRNA), a biotech\u2026", "url": "https://us.acrofan.com/detail.php?number=478397", "urlToImage": "https://mms.businesswire.com/media/20210601006111/en/839474/21/KO_LOGO.jpg", "publishedAt": "2021-06-01T13:00:00Z", "content": "New agreement with Lonza will increase drug substance production in Europe by the fourth quarter 2021\r\nLonza Geleen will support the production of an additional 300 million doses per year\r\nCAMBRIDGE,\u2026 [+10851 chars]"}]}